Figure 1.

(A) Crossing scheme of the single transgenic mice PDGFb-iCreERT2 and Ctnnb1^wt/lox(ex3) or Ctnnb1^lox/lox(ex3) to obtain double transgenic hetero- (Ctnnb1^BM-GOFwt/fl) and homozygous (Ctnnb1^BM-GOFfl/fl) mice. (B) Schedule of tamoxifen injection of double transgenic mice to achieve constitutive activation of β-catenin in MKPs of the BM. Animals were sacrificed 21 days after the last tamoxifen injection. (C) Gross phenotype of mice at 21 days. Inset shows higher magnification of the flaked skin with hair loss in Ctnnb1^BM-GOFw/fl mice. (D) Gross morphological phenotype of spleen derived from Ctnnb1^BM-CTL and Ctnnb1^BM-GOFw/fl mice (n = 4). (E) Quantification of spleen to body weight of Ctnnb1^BM-CTL (n = 12), Ctnnb1^BM-GOFw/fl (n = 12) and Ctnnb1^BM-GOFfl/fl (n = 4) mice. (F) Complete blood cell (CBC) assay from peripheral blood (PB) showing thrombocytes (K/µL) for Ctnnb1^BM-CTL (n = 12), Ctnnb1^BM-GOFw/fl (n = 6) and Ctnnb1^BM-GOFfl/fl (n = 7) mice. (G) CBC assay from PB showing erythrocytes/RBCs (M/µL) for CTL (n = 12), Ctnnb1^BM-GOFw/fl (n = 6) and Ctnnb1^BM-GOFfl/fl (n = 7) mice. (H) Prussian blue staining of spleen cryosections from spleen of Ctnnb1^BM-CTL and Ctnnb1^BM-GOFw/fl mice and (I) quantification of hemosiderin coverage of Ctnnb1^BM-CTL (n = 3), Ctnnb1^BM-GOFw/fl (n = 3) and Ctnnb1^BM-GOFfl/fl (n = 3) mice using ImageJ software 2.9.0/1.53t. (J) Quantitative FACS analysis of leukocytes (myeloid cells: granulocytes, monocytes; lymphoid cells: B and T cells) in peripheral blood Ctnnb1^BM-CTL (n = 15), Ctnnb1^BM-GOFw/fl (n = 7) and Ctnnb1^BM-GOFfl/fl (n = 7). Significance is indicated as follows: *, p < 0.05; ***, p < 0.001.